Patent classifications
A61K9/00
COMPOUNDS, POLYMERS, DEVICES, AND USES THEREOF
Described herein are compounds of Formula (I), polymers and implantable elements comprising compounds of Formula (II), and compositions and methods of use thereof. In particular, the compounds, modified polymers, implantable elements and related compositions may be used in methods for the prevention and treatment of a disease, disorder or condition in a subject.
Therapeutic Engineered Microbial Cell System and Methods for Treating Hyperuricemia and Gout
The present disclosure relates to engineered microbial cells that have been engineered to include a uricase, a uric acid transporter, or both a uricase and a uric acid transporter. The engineered microbial cells of the present disclosure are useful in degrading uric acid inside the engineered microbial cell. The engineered microbial cells of the present disclosure are useful in methods of treating hyperuricemia. The engineered microbial cells of the present disclosure are also useful in methods of treating gout, and in particular chronic refractory gout.
DIHYDROERGOTAMINE MESYLATE FORMULATIONS AND PRE-FILLED INJECTORS FOR THERAPEUTIC DELIVERY OF THE SAME
The present disclosure is directed to formulations and methods for treating or preventing head pain, including migraines, with dihydroergotamine mesylate.
METHODS OF TREATING LYMPHEDEMA WITH DEUPIRFENIDONE
Disclosed herein are methods of treating lymphedema that include administering a clinically effective amount of deupirfenidone.
TREATMENT OF PAIN BY SUBARACHNOID ADMINISTRATION OF SUSTAINED-RELEASE LIPOSOMAL ANESTHETIC COMPOSITIONS
In some embodiments provided herein is a method of treating pain, the method comprising injecting into the subarachnoid space of the subject a pharmaceutical composition comprising: a) a multivesicular liposome comprising: at least one amphipathic lipid, and at least one neutral lipid; and b) an aqueous phase comprising bupivacaine phosphate, wherein the aqueous phase is encapsulated within the multivesicular liposome.
Mucoadhesive Polymeric Drug Delivery Compositions and Methods
This invention provides compositions for controlled localized depositing of one or more drugs within a subject. More particularly, described herein are compositions comprising a) a polyethylene glycol (PEG) composition having a first low molecular weight PEG (Mw between 200-500 Da) and a second low molecular weight PEG (Mw between 500-2000 Da) and b) a mucoadhesive in polymer. Alternatively, composition may comprise a) a polyethylene glycol (PEG) composition having a first low molecular weight PEG (Mw between 200-500 Da) and a second low molecular weight PEG (Mw between 500-2000 Da), b) a water insoluble polymer and c) a mucoadhesive polymer. Furthermore, the composition may further comprise one or more drugs. Also provided are methods of manufacturing and administering the compositions described herein, which are used as biodegradable, injectable mucoadhesive low-viscosity pastes.
METHOD OF PROTECTING A RESPIRATORY TRACT OR A LUNG FROM DAMAGE, METHOD OF PROTECTING A LUNG FROM PRESSURE DAMAGE INDUCED BY A VENTILATOR, METHOD OF SUPPRESSING SPREAD OF INFECTION WITH VIRUSES OR BACTERIA THAT CAUSE PNEUMONIA IN PULMONARY BRONCHIAL EPITHELIAL CELLS OR ALVEOLAR EPITHELIAL CELLS, AND NASAL SPRAY
A method of protecting a respiratory tract or a lung from damage is provided. The method comprises administering a pharmaceutical composition to a patient in need thereof. The pharmaceutical composition comprises trehalose or a trehalose derivative.
DERMATOLOGICAL COLLAR FOR NON-HUMAN ANIMALS
The present invention relates to a collar for non-human animals, preferably for companion animals, comprising a polymeric matrix and a lipid extract comprising sphingomyelins. It also refers to the collar for use as a medicine, particularly for use as an adjuvant and for use in the treatment or prevention of atopic dermatitis or allergic dermatitis, as well as in restoring the integrity of the skin during or after an atopic dermatitis or an allergic dermatitis, increasing the hydration and flexibility of the skin, facilitating skin regeneration or reducing itching of the skin.
Method of Reducing Age-related Systemic Chronic Inflammation
A method of reducing systemic chronic inflammation in a subject by administering a composition capable of reducing the expression level of inflammatory biomarkers.
COMPOSITIONS FOR TOPICAL TREATMENT OF RADIATION DERMATITIS
The present disclosure relates to topical compositions and methods for the treatment of radiation dermatitis. The compositions include a cannabinoid and an oil comprising at least 1 wt % of at least one molecule containing an aliphatic chain with at least one cyclopropyl or cyclopropenyl group, such as a cyclopropene fatty acid or a cyclopropane fatty acid. The compositions can also include other components such as stabilizers, thinners, thickeners, fragrances, moisturizers, emollients; and components that provide anti-irritation or anti-inflammatory properties to the compositions.